Pentixapharm Holding AG
PTPN.DE operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
Business. PTPN.DE is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products, with key performance indicators including pipeline depth, research and development expenditure, and patent expiration risks. Specific details regarding operating segments and geographic presence are not available. The company is listed on the Xetra exchange under the ticker PTPN.DE.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PTPN.DE is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products, with key performance indicators including pipeline depth, research and development expenditure, and patent expiration risks. Specific details regarding operating segments and geographic presence are not available. The company is listed on the Xetra exchange under the ticker PTPN.DE.
The company's capital structure is characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations, and a current ratio of 1.73, suggesting adequate short-term liquidity to cover its liabilities. However, the company's operating cash flow of -17.97 million EUR and free cash flow of -13.41 million EUR indicate a significant cash outflow from operations, which could pressure liquidity in the near term.
Profitability metrics show a return on equity of -47.08% and a return on assets of -39.44%, both of which are negative and significantly below the industry median for pharmaceutical companies. These figures suggest the company is not generating returns for shareholders or effectively utilizing its assets.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the data does not specify revenue distribution across regions, but the company's operations are likely centered in Europe given the EUR financial reporting.
Looking ahead, the company is expected to face a challenging growth trajectory, with no clear revenue growth indicators in the current fiscal year. The operating income of -19.86 million EUR and net income of -16.51 million EUR suggest a continued period of losses, which could impact future growth prospects.
Risk factors include a low liquidity score and the potential for dilution, although no immediate filing-based liquidity or dilution flags were detected. The company's capital expenditure of -625,000 EUR indicates some investment in operations, but the overall financial position remains weak.
Recent events include the publication of the latest financial data, which shows a continued decline in profitability and liquidity. No significant filings or transcripts were reported in the available data, but the company's financial performance remains a concern for investors.
- PTPN.DE is operating at a loss with negative returns on equity and assets.
- The company has no long-term debt but faces liquidity challenges due to negative operating and free cash flows.
- There is no segmental or geographic diversification in the available data, indicating potential concentration risk.
- Analysts have issued a single "buy" recommendation with no strong buy or hold ratings, suggesting limited confidence in the stock.
- The company's capital expenditure is minimal, indicating limited investment in future growth.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PTPN.DE Market data — financials · 2026-05-29
- Pentixapharm Holding AG Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Andreas EckertChairman of the Supervisory Board